Press Release
Feb 15, 2024
Investing in the Next Frontier of Healthcare: Navigating Opportunities in In Vivo Gene Editing Technologies
YolTech Therapeutics operates as a gene editing company at the forefront of medical innovation
Share
LATESTNEWS
-
YolTech Therapeutics Receives FDA IND Clearance to Initiate Global Pivotal Trial of In Vivo Gene-Editing Therapy YOLT-203 for Primary Hyperoxaluria Type 1 (PH1)
Nov 19, 2025
-
YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC
Sep 11, 2025
-
YOLT-203 Receives Orphan Drug Designation from EMA
Jul 28, 2025
